TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Trump Says Anthropic No Longer Seen as National Security Threat 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
NEW YORK, Jan. 12, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Osiris Therapeutics, Inc. (“Osiris Therapeutics”) (NASDAQ:OSIR) between May 12, 2014 through November 20, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. If you purchased or otherwise acquired Osiris Therapeutics between May 12, 2014 and November 20, 2015, your rights may be affected by this action. To get more information go to:
http://zlk.9nl.com/osiris-therapeutics-osir
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Osiris improperly recognized revenue under contracts it had with its distributors; (2) Osiris’ disclosure controls and procedures were not effective as of December 31, 2014, March 31, 2015, and June 30, 2015; and (3) as a result, defendants’ statements about Osiris’ business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Osiris Therapeutics you have until January 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
